P6 Assessment of markers of cardiac toxicity following combined treatment of cardiomyocytes with epirubicin and trastuzumab

Risk Prediction, Diagnosis and Management of a Breast Cancer Patient with Treatment-Related Cardiovascular Toxicity: An Essential Overview

“…Some clinical preclinical analyses of foetal cardiomyocytes exposed to trastuzumab found a reduction in IL6 along with an increase in cell viability when treated with dapaglifozin, a sodium-glucose cotransporter 2 inhibitor, and berberine, a nutraceutical compound [93,94]. This, when taken into consideration with the previously mentioned cardiomyocyte viability testing [64] in those on trastuzumab treatment, suggests a potential future benefit in depressed ejection fraction secondary to cancer treatment. However, IL6 monitoring is not currently in the ESC cardio-oncology guidelines for trastuzumab monitoring [1], and Mantovani et al [95] echoed this sentiment when early myocardial dysfunction found via "speckle tracking" on echo did not correlate with an elevation in IL6 for their HER2 population.…”

“…At 32-month follow-up, they found no significant difference in biomarker levels between the two groups but found a correlation with raised CRP and NP in their cardiotoxicity cohort. Bell et al [64] published a cell viability study via Western blot analysis and polymerase chain reaction of cardiomyocytes in patients treated with trastuzumab and epirubicin. In those in the combined treatment arm, cell viability decreased, as well as a significant increase in troponin-I and BNP levels, suggesting a positive predictive value of the biomarkers.…”